-->

Tag: Kite

Home / Kite

Categories

Kite completes acquisition of Tmunity

Press Release Feb 2023: - Kite, a Gilead Company (NASDAQ: GILD), today announced the completion of the previously announced transaction to acquire Tmunity Therapeutics (Tmunity), a clinical...
kite

Tecartus granted European marketing authorization for treatment of relapsed or refractory acute lymphoblastic leukemia

Sept 2022: The European Commission (EC) has authorized Kite's CAR T-cell therapy Tecartus® (brexucabtagene autoleucel) for the treatment of adult patients 26 years of age and older with relapsed or r...
kite

CAR NK therapy has an effective rate of 73%

Immunotherapy in treatment of cancerCancer CAR-NK therapy has an effective rate of 73%, and is being recruited in domestic clinical trials.Immunotherapy has revolutionized the way cancer is treated. ...
kite

Scan the code